Clinical trial
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited…
NCT00041691 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00041691 |
|---|---|
| Title | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery |
| Official title | A Phase I, Single Dose Escalating Study to Investigate the Tolerability, Pharmacokinetics and Dosimetry of 90 Y-Humanized MN-14 IgG in Colorectal Cancer Patients With Limited Residual Disease After Primary or Salvage Surgery |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms |
| Intervention type | Drug |
| Interventions | hMN14 (labetuzumab) |
| Enrollment | 30 |
| First posted | Jul 15, 2002 |
| Last update posted | Aug 19, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: